Navigation Links
Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
Date:4/15/2008

PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today interim results from two ongoing Phase 1 trials in hormone refractory prostate cancer (HRPC) demonstrating dose-dependent T-cell activation and clinical activity of ipilimumab, an investigational anti-CTLA-4 antibody. These studies were done in combination with antigen-releasing immunotherapies based on GM-CSF, a cytokine that stimulates the proliferation of white blood cells and augments immune responses, and results were presented in two separate oral presentations by investigators at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego.

"The interim results demonstrating clinical activity in these ongoing trials lend additional support to the concept of ipilimumab as part of a therapeutic regimen in treating prostate cancer," said Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We will continue to explore the prospects of ipilimumab in HRPC, and we expect further data in prostate cancer for ipilimumab monotherapy and in combination with other antigen-releasing agents at this year's ASCO conference in June."

-- "Dendritic and T cell functions in patients with metastatic

hormone-refractory prostate cancer treated with GVAX immunotherapy for

prostate cancer and ipilimumab" (Abstract #2538)

Interim data from the ongoing Phase 1 study of escalating doses of

ipilimumab in combination with the Cell Genesys, Inc. GVAX

immunotherapy for prostate cancer (an investigational agent comprised

of whole tumor cells modified to secrete GM-CSF) were presented by

Saskia JAM Santegoets, Ph.D., from the Department of Medical Oncology

and Pathology of Vrije Universiteit Medical Center located in

Amsterdam, Netherlands. The data suggested an ipilimumab dose-related

association with increased T-cell activation, as well as associated

anti-tumor activity from the initial 12 patients that was previously

reported at the June 2007 American Society of Clinical Oncology (ASCO)

meeting.

In the Phase 1 clinical trial, 28 patients with metastatic HRPC have

been enrolled, including 12 patients in the dose-escalation cohort

(0.3, 1, 3 or 5 mg/kg ipilimumab) and 16 patients in the expansion

cohort (3 mg/kg ipilimumab). The dose of GVAX immunotherapy for

prostate cancer used in this combination trial is comparable to that

currently being evaluated in Cell Genesys' ongoing Phase 3 program. The

treatment combination was generally well-tolerated. Adverse events

associated with this regimen are consistent with data previously

reported from this study.

-- "CTLA-4 blockade for hormone refractory prostate cancer: dose-dependent

induction of CD8+ T cell activation and clinical responses" (Abstract

#2539)

Preliminary data from an ongoing Phase 1 study of escalating doses of

ipilimumab in combination with GM-CSF (sargramostim) were presented by

Lawrence Fong, Ph.D., from the University of California, San Francisco,

San Francisco. Of the six patients treated at 3 mg/kg ipilimumab, three

experienced confirmed decreases in prostate-specific antigen (PSA)

serum levels of over 50%, and one of these patients experienced a

partial response in hepatic metastases.

In the Phase 1 clinical trial, 26 patients with HRPC received treatment

with a 28-day cycle of daily doses of 250 mg/m2 of GM-CSF for 14 days

in combination with ipilimumab administered on the first day of the

28-day cycle for up to four cycles. Ipilimumab dosing initially ranged

from 0.5 mg/kg to 3 mg/kg. Additional patients are now being treated

with higher doses (5 mg/kg and 10 mg/kg) of ipilimumab. The treatment

combination was generally well-tolerated. Adverse events associated

with ipilimumab treatment are consistent with data previously reported

from this study and from other clinical trials of ipilimumab.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein relating to the interim data from ongoing ipilimumab combination Phase 1 studies may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "preliminary"; "interim"; "potential"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 In response to the ... FDA,s Deputy Commissioner for Medical Products and Tobacco, along with ... reassess the agency,s approach to opioid medications. The plan will ... providing patients in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ...
(Date:2/4/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... investigational kinase medicines for patients with genomically defined ... of directors of Lonnel Coats , a ... industry-related experience. Jeffrey Albers , ... strategic experience developing and commercializing numerous oncology products ...
(Date:2/4/2016)... SIOUX FALLS, S.D. , Feb. 4, 2016 ... patient and guest technology solutions, today announced that ... SONIFI Health Senior Living Engagement System. The system ... information tool that residents access through a tablet ... --> The resident engagement system provides access ...
Breaking Medicine Technology:
(Date:2/7/2016)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... Friday in recognition of National Wear Red Day. National Wear Red Day is ... and stroke in women. Heart disease and stroke cause 1 in 3 deaths among ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , ... the world with an estimated 5000 perioperative nurses in attendance to study ...
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds and Kevin ... of a new DRTV campaign with Belly Bands. , Having a dog is great—except ... to puppy pads and find nothing works, get Belly Bands, the easiest way ...
(Date:2/5/2016)... ... 05, 2016 , ... Love is in the air at King Kullen! The ... and packaging. This staple for Valentine’s Day is a must-have, and can be picked ... Day, not only are long-stem roses available, but also other flower bouquets, elegantly wrapped ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... setting the stage for new clinical and scientific initiatives have all marked the ... she was appointed President and CEO of the nation’s oldest cancer center, Candace ...
Breaking Medicine News(10 mins):